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Despite stringent governmental regulations,
lead exposure continues to be a major public
health problem, with blood levels being ele-
vated in a bimodal distribution predomi-
nantly affecting young children 1–5 years of
age and individuals > 50 years of age (Pirkle
et al. 1998). The Centers for Disease Control
and Prevention’s (CDC’s) Childhood Lead
Surveillance Program monitors blood Pb at
the state and local levels. Mean national blood
Pb levels have decreased dramatically over the
past 30 years, as documented by the third
National Health and Nutrition Examination
Survey, Phase 2 (NHANES, 1991–1994)
(CDC 2000; Pirkle et al. 1998). According to
NHANES data from 1999 and CBLS data
from 1996–1998, despite the decreases in
mean national blood Pb among children, lev-
els remain elevated in speciﬁc areas, affecting
mostly low-income, urban children and those
living in older housing (CDC 2000).
In addition to children, many adults
maintain elevated blood levels due to past
occupational or environmental exposure.
With the reduction of Pb in fuel and soldered
cans as well as increased awareness and vigi-
lance, acute environmental Pb exposure has
decreased dramatically (Pirkle et al. 1998).
However, Pb becomes sequestered in the
skeleton, incorporated into hydroxyapatite
crystals during calcification, and remains
there until the bone is resorbed or remodeled
(Wittmers et al. 1988).
Elevated blood Pb levels, particularly peri-
menopausal, may have a causative role in the
pathogenesis of the costly metabolic bone dis-
ease osteoporosis. Blood Pb levels increase dur-
ing periods of high bone turnover such as
menopause (Silbergeld et al. 1988, 1993).
Additionally, the aging process itself has been
shown to increase the release of Pb from the
skeleton by cadaveric analysis as well as by
experimental study (Barnes et al. 1999). In vivo
models have demonstrated a decrease in bone
density with Pb exposure (Escribano et al.
1997; Gruber et al. 1997). In addition, multi-
ple reports in humans and animals support a
role for Pb in osteopenia (Berlin et al. 1995;
Silbergeld et al. 1988). The decrease in bone
quality may not only cause individuals to cross
a fracture threshold earlier, but, we hypothesize,
it may also impede normal fracture healing.
It is widely appreciated that the role of the
skeleton in Pb toxicokinetics is greater than
that of a reservoir. Several authors have
described the inverse relationship between ele-
vated blood Pb levels and skeletal develop-
ment, chest circumference, and stature (Pearl
and Boxt 1980; Schwartz et al. 1986; Shukla
et al. 1989). The effects on adults are more
subtle. Previously, we identiﬁed chondrocytes
as important targets of Pb toxicity (Puzas et al.
1992) and demonstrated that Pb suppresses
the expression of phenotypic markers in
growth plate chondrocytes (Hicks et al. 1996).
More recently, we have shown that Pb alters
the effects of parathyroid-hormone–related
peptide, transforming growth factor-β
(TGF-β), activator protein-1, and nuclear
factor-κB signaling in chondrocytes (Zuscik
et al. 2002). Histomorphometric studies have
demonstrated a significant Pb-associated
decrease in length of rat femoral growth plate
cartilage (Gonzales-Riola et al. 1997).
Together, these data suggest an inhibitory
effect on endochondral ossiﬁcation (Gonzales-
Riola et al. 1997; Hicks et al. 1996).
Several authors have demonstrated adverse
effects of Pb on both bone formation and
resorption mediated by cellular pathways
affecting osteoblasts and osteoclasts (Dowd
et al. 1990; Long et al. 1990; Miyahara et al.
1994; Pounds et al. 1991; Schanne et al.
1989, 1990). Osteoblasts are known targets of
Pb toxicity from in vitro studies with ROS
17/2.8 cells, which demonstrated suppression
of alkaline phosphatase, type I collagen, and
osteocalcin (Long et al. 1990). In addition,
circulating levels of osteocalcin, which serve as
markers of osteoblast activity and regulators of
bone formation and remodeling (Ducy et al.
1996), are decreased in Pb-intoxicated chil-
dren (Markowitz et al. 1988). The mechanism
by which these effects occur remains unclear.
Fracture healing is a complex orchestra-
tion of several cell types. It is unique in that
healing occurs by reformation of bone rather
than scar tissue. Fracture healing involves pri-
mary recruitment, proliferation, and differen-
tiation of both osteoprogenitors (osteoblast
progenitors), for intramembranous ossifica-
tion, and undifferentiated mesenchymal cells,
for endochondral bone formation (Barnes
et al. 1999; Einhorn 1998). Fracture healing is
an established means of studying the forma-
tion and repair of skeletal elements in vivo as
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Lead exposure continues to be a signiﬁcant public health problem. In addition to acute toxicity, Pb
has an extremely long half-life in bone. Individuals with past exposure develop increased blood Pb
levels during periods of high bone turnover or resorption. Pb is known to affect osteoblasts, osteo-
clasts, and chondrocytes and has been associated with osteoporosis. However, its effects on skeletal
repair have not been studied. We exposed C57/B6 mice to various concentrations of Pb acetate in
their drinking water to achieve environmentally relevant blood Pb levels, measured by atomic
absorption. After exposure for 6 weeks, each mouse underwent closed tibia fracture. Radiographs
were followed and histologic analysis was performed at 7, 14, and 21 days. In mice exposed to low
Pb concentrations, fracture healing was characterized by a delay in bridging cartilage formation,
decreased collagen type II and type X expression at 7 days, a 5-fold increase in cartilage formation at
day 14 associated with delayed maturation and calciﬁcation, and a persistence of cartilage at day 21.
Fibrous nonunions at 21 days were prevalent in mice receiving very high Pb exposures. Pb signiﬁ-
cantly inhibited ex vivo bone nodule formation but had no effect on osteoclasts isolated from Pb-
exposed animals. No signiﬁcant effects on osteoclast number or activity were observed. We conclude
that Pb delays fracture healing at environmentally relevant doses and induces ﬁbrous nonunions at
higher doses by inhibiting the progression of endochondral ossiﬁcation. Key words: endochondral
ossiﬁcation, fracture healing, lead, osteoblast, osteoclast, Pb, Pb toxicity. Environ Health Perspect
113:749–755 (2005). doi:10.1289/ehp.7596 available via http://dx.doi.org/ [Online 14 March 2005]well as the crucial signaling pathways involved
(Zhang et al. 2002).
Given the known effects on cells involved
in bone formation and remodeling and the
absence of literature on Pb in skeletal repair,
the purpose of the present study was to evalu-
ate the effects of elevated blood Pb levels on
fracture healing. We employed an established
murine tibia fracture model (Bonnarens and
Einhorn 1984; Einhorn 1998) to characterize
the effects of Pb on skeletal repair.
Materials and Methods
Pb exposure and whole blood Pb level determi-
nation. All Pb solutions were made using Pb
acetate (Gibco, Grand Island, NY) dissolved in
distilled water. All mice had unrestricted access
to the normal rodent diet supplied by the
vivarium staff, and drinking water was replen-
ished at least one time per week by the inves-
tigative staff to ensure continuous Pb exposure.
All Pb waste solutions were disposed of appro-
priately. Mice were housed in groups of ≤ 5
animals per microisolator cage in the vivarium
and maintained on a 12-hr light/dark cycle.
All procedures were carried out in accordance
with the regulations of and following the
approval of the University of Rochester
Animal Use and Care Committee.
Female C57/Bl6 mice (n = 32) at 6 weeks
of age were divided into eight groups of four
mice each. Each group was exposed to one of
the following doses: 0, 55, 230, 580, 1,160,
1,750, 2,300, or 5,800 ppm Pb in the drinking
water. This preliminary exposure was carried
out to determine the whole-blood Pb (BPb)
concentrations needed to approximate envi-
ronmentally relevant levels of human exposure.
This cohort is referred to as group A. Pb expo-
sures of 0, 55, and 230 ppm Pb in the drinking
water were selected as most environmentally
relevant. A second cohort (group B) of female
C57/Bl6 mice (n = 54) was divided into three
groups of 18 animals and housed under condi-
tions as outlined above. All experiments
related to the analysis of the fracture healing
process were performed with group B except
one, which documented chronic nonunions in
mice exposed to 2,300 ppm Pb.
Before Pb exposure, 100 µL whole blood
samples were collected for baseline BPb level
measurement. Samples were collected, using
the saphenous vein technique (Hem et al.
1998), into 100 µL nitric acid–washed volu-
metric capillary tubes (VWR, Buffalo Grove,
IL). Each whole-blood sample was then
immediately diluted 1:10 with a matrix modi-
fier solution containing 0.2% NH4H2PO4,
0.5% Triton X-100, and 0.2% HNO3
(Parsons 1993). Whole blood was collected
for BPb analysis at 3-week intervals.
BPb levels were determined using a Perkin-
Elmer AAnalyst 600 atomic absorption spec-
trophotometer equipped with longitudinal
Zeeman background correction and a trans-
verse heated graphite furnace (PerkinElmer
Life and Analytical Sciences, Boston, MA).
This method was adapted by Parsons from the
Department of Environmental Health and
Toxicology, SUNY at Albany (Parsons 1993).
All instruments, plastic, and glassware were
periodically tested for Pb contamination by
atomic absorption throughout these experi-
ments. In addition, the accuracy of our atomic
absorption technique was verified using
Standard Reference Material 1486 bone meal
(National Institute of Standards and
Technology, Gaithersburg, MD).
Bone Pb determination. After 6 weeks,
four animals from each of the 0, 55, 230,
2,300, and 5,800 ppm Pb groups were sacri-
ficed. The femora and tibiae were removed,
the epiphyses and soft tissues were discarded,
and the bone marrow was ﬂushed out with a
25-gauge 5/8-inch needle (Becton-Dickinson,
Franklin Lakes, NJ). The remaining diaphy-
seal bones were washed with phosphate-
buffered saline (PBS) to remove all marrow
elements and blood cells. The bones were
then processed as described previously
(Parsons 1993). Briefly, cortical bones were
dried in a vacuum at 60°C overnight. They
were then weighed dry in Teflon digestion
vials (Savillex, Minnetonka, MN). Bones
were wet washed with 5 mL ultrapure nitric
acid 67–70% (SeaStar Chemicals, British
Columbia, Canada) in the Teflon vials and
taken to dryness after reﬂuxing for 3 hr. The
bone ash was then resuspended in 1 mL
HNO3, and the total volume was brought to
10 mL with distilled water and analyzed.
Bone marrow osteoblast differentiation.
Group B animals were sacriﬁced after 6 weeks
of Pb exposure. The femora and unfractured
tibiae were excised, and the soft tissues were
removed. Primary bone marrow cells were iso-
lated and prepared as described previously
(Franzoso et al. 1998; Zhang et al. 2002). Bone
marrow cells were cultured in α-minimal essen-
tial medium (α-MEM) with 10% fetal bovine
serum (FBS; Hyclone Laboratories, Logan,
UT) and 1% penicillin/streptomycin (Gibco)
for 3 days. On the 4th day, nonadherent cells
were washed off. The cells were then cultured
in complete osteoblast medium of α-MEM
with 10% FBS, 50 µM ascorbic acid, 1% peni-
cillin/streptomycin, and 5 mM β-glycerophos-
phate. The cells were plated at 2 × 106 cells per
6-cm plate for nodule formation assays, and
medium was changed every 3 days. After
17 days in culture, triplicate cultures were ﬁxed
with 10% formalin, rinsed in distilled water,
and stained by von Kossa’s method (Sigma
Chemical Co., St. Louis, MO). Total nodular
area was quantiﬁed by histomorphometry.
Osteoclast precursor isolation. Osteoclast
progenitor cells (OCPs) were prepared from
splenocytes as described previously (Schwarz
et al. 1997). Animals were sacrificed after
6 weeks. Spleens were removed aseptically and
placed in 10 mL Dulbecco’s Modified Eagle
Medium (DMEM; Gibco). The organs were
homogenized and washed through a wire mesh
with 10 mL DMEM supplemented with 10%
FBS and 1% penicillin/streptomycin. The cells
were spun at 1,600 rpm for 5 min and then
resuspended in 1 mL α-MEM, after lysing
erythrocytes with cold ammonium chloride.
Osteoclastogenesis. Splenocytes were seeded
at 1.75 × 105 cells/well in a 96-well plate in
α-MEM supplemented with macrophage-
colony–stimulating factor (M-CSF; 30 ng/mL)
and receptor activator nuclear factor κB ligand
(RANKL; 100 ng/mL). Fifty percent medium
was added the next day, and medium was
changed every other day thereafter. Cultures
were incubated at 37°C for 6–7 days and then
fixed and stained for tartrate-resistant acid
phosphatase (TRAP) using the leukocyte acid
phosphatase kit (Sigma). The number of
TRAP+ multinucleated cells was then counted
to quantify osteoclast formation as described
previously (Zhang et al. 2001).
Flow cytometry. Surface protein staining
was performed on splenocytes. After erythro-
cyte lysis, a single-cell suspension was incu-
bated in DMEM with 10% FBS. Cells were
harvested in PBS containing 5 mM EDTA and
stained for CD11b with biotin-labeled anti-
bodies, as described previously (Li et al. 2004).
Data were acquired using a FACScalibur
cytometer and analyzed with Cell Quest soft-
ware (Beckton Dickenson, Bedford, MA).
Macrophage colony-forming assay. The
in vitro colony-forming assay was performed as
described previously (Franzoso et al. 1997).
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Table 1. In vivo Pb bone exposures.
Pb in drinking water (ppm) µg Pb/g dry bone
0 0.08 ± 0.01
55 33.3 ± 2.80
230 117.3 ± 11.13
2,300 472.88 ± 61.98
5,800 682.41 ± 142.75
n = 4/treatment group. Data presented are mean ±SD.
Figure 1. In vivo Pb exposures in group A mice (n =
4/group). Mice were exposed continuously to Pb in
drinking water for the indicated time; see “Materials
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6 weeksFreshly isolated splenocytes were plated at
105 cells/mL in a 35-mm dish. Splenocytes
were cultured in methylcellulose-based
medium (StemCell Technologies, Vancouver,
British Columbia, Canada) supplemented with
M-CSF (30 ng/mL) for 12 days. Individual
colonies, deﬁned as > 40 cells, were then quan-
tiﬁed under an inverted microscope. The total
number of colonies represents the original
number of monocyte/macrophage and osteo-
clast precursors (Schwarz et al. 1997).
Bone resorption assay. Splenocytes were
seeded at 1.75 × 105 cells/well on sterile
4 mm × 4 mm bovine femoral cortical bone
wafers. Cells were cultured in α-MEM with
10% FBS supplemented with M-CSF
(30 ng/mL), RANKL (100 ng/mL), 1%
L-glutamine, 1% penicillin/streptomycin, and
1% nonessential amino acids (Gibco). Fifty
percent medium was added the next day, and
medium was changed every other day there-
after. After 12 days, the wafers were scraped,
dried, stained with toluidine blue, and exam-
ined under a 40× objective. Wafer images
were captured, and resorption pits on the
wafer surface were traced to determine the
total pitted area using Osteometrics software
(Osteometrics, Atlanta, GA) as described pre-
viously (Childs et al. 2001).
Fracture. After 6 weeks of Pb exposure,
mice were anesthetized by intraperitoneal
injection of 100 mg/kg ketamine HCl and
15 mg/kg xylazine. After adequate sedation,
the surgical site was prepared with 70%
ethanol and an incision was made about the
left knee. A 25-gauge 5/8-inch needle was
inserted lateral to the patellar tendon and into
the tibial marrow space. This needle was then
removed and a 0.25-mm diameter insect pin
(Fine Science Tools, Foster City, CA) was
placed into the tibia. The pin was trimmed
proximally at the level of the tibial plateau.
The wound was then closed with 4–0 nylon
sutures. The left tibiae were placed in a modi-
ﬁcation of the guillotine three point-bending
device described by Bonnarens and Einhorn
(1984) and Hiltunen et al. (1993). The tibial
diaphyses were fractured, without trauma to
the overlying skin, using a force exerted by a
540 g weight dropped 16.5 cm. Radiographs
characterized the fracture and confirmed
intramedullary fixation. Radiographs were
obtained using a Faxitron cabinet X-ray sys-
tem (Faxitron, Wheeling, IL). The radio-
graphic exam was repeated at 7-day intervals
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Figure 2. Radiographic analysis of the Pb effects on
fracture healing in group B mice (n = 6/group).
Mice were continuously exposed to Pb in drinking
water for 6 weeks, with X rays from representative
mice taken at the indicated time after fracture. See
“Materials and Methods” for details. Arrows indi-
cate the radiolucency in the day-14 fracture callus
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Figure 3. Histologic analysis of the Pb effects on fracture healing in group B mice continuously exposed to
Pb in drinking water for 6 weeks (n = 6/group). See “Materials and Methods” for details. ABH/OG histology
sections are shown at 10× magnification. Note the large amount of Alcian blue–stained cartilage in the
day-14 fracture callus of Pb-treated mice (E, F). The immature fracture callus has less cartilage and exhibits
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Figure 4. Histomorphometry of the fracture callus of group B mice continuously exposed to Pb in drinking
water for 6 weeks (n = 6/group). See “Materials and Methods” for details. No signiﬁcant differences were
found between the groups at 7 and 21 days (data not shown) or between the amount of ﬁbrotic tissue (A)
and osteoclast numbers (D) between the groups. However, Pb signiﬁcantly increased the amount of carti-
lage (B) and decreased the amount of bone (C) present in the day-14 fracture calluses of exposed mice.
Error bars indicate SE.
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Pb in drinking water (ppm) Pb in drinking water (ppm)to follow healing and confirm maintenance
of ﬁxation.
Histology. Fractured tibiae were harvested
at 7, 14, and 21 days. The tissues were ﬁxed
in 10% formalin for 24 hr and decalciﬁed in
10% EDTA at pH 7.2 for 2 weeks. Samples
were then processed, embedded in paraffin,
and cut in 3-µm sagittal sections. Three con-
tiguous sections (100 µm apart) for each spec-
imen were stained with Alcian blue and
counterstained with hematoxylin, orange G,
and eosin (ABH/OG) as described previously
(Zhang et al. 2002). Additional contiguous
sections were stained for TRAP activity using
naphthol AS-BI phosphate and counter-
stained with hematoxylin (Sigma).
Fracture histomorphometry. Quantitative
analysis was performed on the sagittal
ABH/OG- and TRAP-stained sections by
histomorphometric analysis using Osteometrics
software. Bone and cartilage formation was
quantiﬁed on ABH/OG-stained slides by out-
lining the perimeter of the fracture callus under
the 2× objective. Areas of new woven bone and
cartilage were then traced. This procedure was
repeated until the entire fracture callus had
been evaluated. The areas of woven bone, carti-
lage, and total fracture callus were obtained
directly in square millimeters from the soft-
ware. The amount of mesenchymal tissue was
then calculated by subtracting bone and carti-
lage area from the total callus area. Bone, carti-
lage, and mesenchymal tissue areas each were
expressed as a percentage of total fracture cal-
lus. Osteoclast quantification was performed
on the TRAP-stained slides. Using the 10×
objective, the perimeter of fracture callus was
outlined and individual TRAP positive osteo-
clasts were identiﬁed and counted. The entire
fracture callus was evaluated. The number of
TRAP+ osteoclasts was then expressed per total
area of fracture callus.
In situ hybridization. Plasmids corre-
sponding to osteocalcin, collagen type II
(Col II), and collagen type X (Col X) were
used to synthesize 35S-labeled sense and anti-
sense riboprobes as described previously
(Ferguson et al. 1999; Zhang et al. 2002). Cut
sections were incubated in hybridization
buffer (50% formamide, 0.3 M NaCl, 20 mM
Tris HCl, 5 mM EDTA, 10% dextran sulfate,
0.02% Ficoll, 0.02% bovine serum albumin,
0.02% polyvinyl pyrrolidone, and 0.5 mg/mL
yeast RNA) containing each riboprobe at
10,000 cpm/µL, and hybridization was per-
formed at 55°C overnight. Nonspecifically
bound probe was hydrolyzed with RNase A
(20 µg/µL) and washed at high stringency at
55°C with 2× salt sodium citrate/50% for-
mamide (Ferguson et al. 1999). Emulsion-
dipped slides were exposed to beta emissions
for 14 days.
Statistics. Data are expressed as mean ±
SEM. Statistical signiﬁcance was determined
using the Student t-test and analysis of variance
(ANOVA) where appropriate. A value of
p ≤ 0.05 was accepted as statistically signiﬁcant.
Results
Pb exposure and whole-blood/bone Pb level
determination. We established a reproducible
murine Pb dosing protocol by introducing var-
ious concentrations of Pb into the drinking
water of group A animals and determining
BPb levels, similar to our rat exposure protocol
(Cory-Slechta et al. 1997). We noted that BPb
levels are quite variable after short-term expo-
sure (1–2 weeks), whereas treatments from 3 to
6 weeks resulted in stable levels (Figure 1). To
assure that this treatment resulted in soft and
hard tissue exposure, we determined the Pb
content in blood and bone (Table 1). These
data indicate that oral dosing leads to environ-
mentally relevant exposures (10–40 µg/dL) and
that BPb measurements faithfully reﬂect organ
exposure in vivo. Additionally, mice appear to
be very tolerant to these Pb exposures. No
gross physical or behavioral changes were
noted in animals with BPb levels three to four
times greater than a lethal human exposure,
in preliminary experiments. There was no 
statistically signiﬁcant difference by ANOVA
testing in body weight among the various dose
groups in unpublished preliminary experi-
ments (data not shown).
Pb inhibits fracture healing. By 14 days
after fracture, all animals showed radiographic
evidence of fracture callus formation (Figure 2).
However, radiographs of Pb-exposed animals
demonstrated a marked increase in radio-
lucency within the fracture callus compared
with controls (Figure 2D–F). At 21 days, all
groups showed evidence of remodeling of the
fracture callus with no remarkable difference
in the three groups (Figure 2G–I).
Consistent with our radiographic ﬁndings,
histologic analysis revealed no remarkable dif-
ferences at 7 and 21 days because all fracture
sites consisted of undifferentiated mesenchyme
and ﬁbrocartilage at the early time point and
remodeling bone at the latter time point
(Figure 3). In our day 14 untreated animals,
we see the normal pattern of newly formed
bone through a cartilage intermediate, as
evidenced by the areas of Alcian blue–stained
cartilage throughout the callus (Figure 3D).
However, in the 14-day Pb-treated groups,
immature cartilage accounts for the large
Article | Carmouche et al.
752 VOLUME 113 | NUMBER 6 | June 2005 • Environmental Health Perspectives
Figure 5. Inhibition of cartilage maturation in day-14 fracture callus of group B mice continuously exposed
to Pb in drinking water for 6 weeks (n = 6/group). Histology sections parallel to those presented in
Figure 3D–F used for in situ hybridization to radiolabeled antisense probes for Col II (A–C), Col X (D–F), or
osteocalcin (OC; G–I) or stained for TRAP (J–L). There is increased Col II signal in the middle of the
Pb-exposed fracture callus (B, C) compared with controls, and there is an absence of Col X (E, F), osteo-




TRAPradiolucency identified by X ray (Figure
3E–F). Histomorphometry of the day 14 frac-
ture calluses showed a significant delay in
endochondral ossification because the Pb-
treated mice had a 4- to 5-fold increase in
unmineralized cartilage with a commensurate
decrease in bone (Figure 4). Interestingly, there
was a nonlinear response to the effects of Pb on
bone tissue because a similar effect was seen in
both the 55 and 230 ppm treatment groups.
In situ hybridization and TRAP staining
in the 14-day fracture group helped assess
phenotypic gene expression and quantify
osteoclasts in the fracture callus, respectively
(Figure 5). Robust expression of Col II,
decreased expression of Col X, and absence of
both the mature osteoblast marker osteocalcin
and TRAP+ osteoclasts were noted in Pb-
treated animals. This confirmed the preva-
lence of immature cartilage in the fracture
callus. Importantly, gene expression outside
of this immature cartilage was indistinguish-
able from untreated controls (Figure 5A–I), as
was osteoclast number (Figures 4 and 5J–L).
Thus, low Pb exposures did not completely
inhibit any process of fracture healing.
Rather, Pb delayed endochondral ossiﬁcation.
A cohort of group A mice (n = 4) were
exposed to 2,300 ppm Pb and analyzed radio-
graphically and histologically. In contrast to
the lower-dose treatment groups (group B),
the radiolucency in the day-14 X rays was not
accompanied by surrounding fracture callus
(Figure 6A). Furthermore, histology failed to
identify evidence of endochondral ossiﬁcation
at the fracture site. Day 21 specimens con-
firmed fibrous nonunions in 75% of the
group A 2,300 ppm animals (Figure 6B–C).
Thus, Pb can completely inhibit fracture heal-
ing at very high doses.
The direct effects of Pb on chondrocytes
(Zuscik et al. 2002), osteoclasts (Bonucci et al.
1983), and osteoblasts (Klein and Wiren 1993;
Long et al. 1990; Pounds et al. 1991) have
been previously documented. Our experiments
on cells isolated from Pb-exposed animals
focus on the mechanism by which Pb inhibits
fracture healing by determining its effects on
progenitor cells. When osteoprogenitor cell dif-
ferentiation was examined using a bone nodule
formation assay, von Kossa staining revealed
that Pb-treated animals produced signiﬁcantly
fewer nodules at both the 55 ppm and
230 ppm dosing regimens (Figure 7). Because
there was no Pb exposure in the culture
medium during osteoblast differentiation, we
interpret these results as a reduction in the total
number of osteoprogenitor cells.
We found no effect on OCP number or
function from in vivo Pb exposure. Flow
cytometry analysis on splenocytes to deter-
mine the CD11b+ OCP frequency showed no
signiﬁcant Pb effects on the number of OCPs
(Figure 8A). By culturing these cells with
RANKL and M-CSF, we were also able to
show that their potential to form osteoclasts
(Figure 8B–C) and resorb bone (Figure 8D)
was not affected by in vivo Pb exposure.
These results are consistent with the fracture
callus histology and indicate that in vivo Pb
has differential effects on mesenchymal versus
myeloid progenitors.
Discussion
Toxicity due to Pb exposure remains a major
public health concern and presents a broad
spectrum of pathologies in children and adults.
Over the last decade, our group has focused on
the effects of Pb on bone and cartilage and its
potential role in osteoporosis (Campbell et al.
2004; Puzas et al. 2004). Because the clinical
manifestation of osteoporosis is fracture and
because fracture healing is a proven model for
examining cellular and molecular aspects of
skeletal repair, we evaluated the effects of
in vivo Pb exposure on callus formation, matu-
ration, and remodeling. In addition to osteo-
porosis, Pb exposure is known to contribute to
dental caries (Moss et al. 1999) and complica-
tions of skeletal growth in children (Kafourou
et al. 1997) via poorly deﬁned mechanisms. As
such, elucidation of the Pb effects on angio-
genesis, stem cell recruitment, endochondral
ossification, osteoclastogenesis, and bone
remodeling during fracture healing could also
have implications for these other human condi-
tions. Additionally, individuals who have high-
injury-risk occupations and are concurrently
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Figure 6. Pb exposure in group A mice (n = 4) exposed to 2,300 ppm Pb for 6 weeks, fractured, and assessed
for skeletal repair. See “Materials and Methods” for details. A day-14 X ray from a representative mouse
demonstrates the limited radiographic healing (arrow) in these mice (A). ABH/OG-stained histology section
of day 21 fracture callus from a representative mouse at 10× (B) and 40× (C) magnification confirms the
presence of ﬁbrotic tissue between the fractured ends of the tibia and the complete absence of endochon-
dral bone formation. These ﬁndings indicate a ﬁbrous nonunion.
Figure 7. Inhibition of osteoprogenitor cells in group
B mice (n = 6/group) continuously exposed to Pb in
drinking water for 6 weeks. See “Materials and
Methods” for details. (A) Representative photo-
graphs of the von Kossa–stained plates. (B) Bone
nodules in these plates quantified as the percent-
age of nodule area as described in “Materials and
Methods.”
*p < 0.05 determined using ANOVA.






























Pb in drinking water (ppm)exposed to Pb may also be susceptible to
fracture nonunions.
Our first aim was to develop a repro-
ducible dosing regimen that could achieve
stable BPb levels over time. For this study we
chose < 3, 15, and 40 µg/dL in whole blood
as our targets of human background, interme-
diate, and high Pb exposures, respectively. We
found a tight correlation between the drink-
ing water concentration and BPb levels
(Table 1) that was similar to our observations
in rats (Cory-Slechta et al. 1997). We veriﬁed
the incorporation of Pb into hard and soft tis-
sues (Figure 1B), which revealed similar con-
centrations to those previously reported in
bone (Pounds et al. 1991). Of interest, no
gross toxic effects of very high BPb exposures
(~ 400 µg/dL) were noted. Because this is
three to four times the lethal dose in humans,
future studies using murine models with
human extrapolation may need to consider
higher dosing.
In this study, remarkable effects of Pb on
fracture healing were clearly apparent, even at
the lowest dose (Figures 2–5). The phenotype
can be described as an increase in chondrogen-
esis and delay in endochondral maturation,
vascular invasion, and resorption. Although
fracture healing is a highly ordered biologic
process that requires precise temporal and spa-
tial regulation, it is known that various com-
pensatory mechanisms have evolved to rescue
healing under adverse conditions. In our expe-
rience with various drug treatments and genet-
ically deficient strains, essentially all closed
stable fractures heal in mice (Flick et al. 2003;
Zhang et al. 2002). Thus, the ﬁnding that the
profound Pb-induced phenotype on day 14 is
completely resolved by day 21 is not surpris-
ing. However, the presence of fibrous
nonunions in three out of four mice with very
high Pb exposure is remarkable given that all
other mice studied (n > 100) healed. Because
it is well known that mice have an extremely
robust ability to heal fractures, we speculate
that mice healed fractures at Pb exposures at
which humans could not.
Although the precise mechanism by which
Pb inhibits fracture-healing remains a topic for
future investigation, the phenotype is very
reproducible and is somewhat reminiscent of
phenotypes described in other mouse models.
The increased chondrogenesis observed is simi-
lar to that seen in the fracture callus of parathy-
roid hormone and prostaglandin-treated mice,
indicating that Pb may be an agonist of protein
kinase A signaling in chondrocytes, as pre-
dicted in our in vitro studies (Zuscik et al.
2002). The literature provides three potential
explanations for the persistence of cartilage in
the fracture callus. The first is a defect in
chondrocyte apoptosis, as seen in mice with
defective tumor necrosis factor receptors
(Gerstenfeld et al. 2001). The second is a
defect in vascular invasion of the cartilage, as
seen in the matrix metalloproteinase-9 knock-
out mice (Colnot et al. 2003). The third is the
inhibition of mesenchymal stem cell differenti-
ation into osteoprogenitors, as seen in mice
deficient in cyclo-oxygenase-2 (Zhang et al.
2002), which is required for callus mineraliza-
tion. Evidence for this mechanism is supported
by our ﬁnding that Pb-treated animals have a
significant decrease in osteoprogenitor fre-
quency (Figure 7). An additional possibility is
inhibition of osteoclastic resorption and
remodeling of the fracture callus, as seen in
mice with defective M-CSF and RANKL sig-
naling. However, our findings that in situ
osteoclast numbers (Figures 4, 5) and OCP
frequency (Figure 8) are unaffected by in vivo
Pb exposure renders this possibility less likely.
The overall clinical significance of Pb
inhibition of fracture healing relates to per-
sons with osteoporosis. We have argued that
because of the high environmental Pb expo-
sures from the 1940s to 1960s, women cur-
rently going through menopause are at an
additional risk of osteoporosis (Puzas et al.
2004). It is now well recognized that factors
released from bone during resorption, such as
TGF-β, can act on cells in the bone marrow
stimulating factors or to inhibit osteoblastic
new bone formation (Evans et al. 1989; Yin
et al. 1999). As a consequence of the high
bone turnover, which would release Pb from
its inactive state in bone hydroxyapatite crys-
tals, an additional imbalance of bone resorp-
tion over formation would occur from Pb’s
preferential toxic effects on osteoblasts. Our
results indicate that osteoporotic, Pb-exposed
Article | Carmouche et al.
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Figure 8. Lack of effects on osteoclast precursors after in vivo Pb exposure. M1, gate used to distinguish
between CD11b-positive and -negative cells on the FACScalibur cytometer. Splenocytes from group B mice
(n = 6/group) were used to determine the CD11b+ OCP frequency by ﬂow cytometry analysis (A) or cultured
in M-CSF and RANKL to form osteoclasts on tissue culture plates (B, C) or on cortical bone wafers (D). We
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observed no signiﬁcant differences in OCP frequency (A), TRAP-stained osteoclast morphology at 10× mag-
to induce the production of osteoclasticpatients may sustain a fragility fracture earlier
and heal their fractures at a slower rate com-
pared with non-Pb-exposed osteoporotic
individuals. Future investigations into the
molecular mechanisms of Pb effects on osteo-
porosis and fracture healing are warranted.
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